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Introduction: Although the atrial ﬁbrillation cycle length (FCL) is considered to shorten in
persistent atrial ﬁbrillation (AF) as a result of electrical remodeling, whether a long-term
change remains in FCL in patients with left ventricular (LV) dysfunction is uncertain.
Morphological properties of AF waves were analyzed in patients with dilated cardiomyopathy
(DCM). Methods and Results: The study population consisted of 43 patients with persistent
AF, and they were divided into a DCM group (n ¼ 14) and a control group (n ¼ 29).
Fibrillation waves from surface ECG lead V1 were puriﬁed by subtracting the QRS-T
complex template. Power spectral analysis was performed by Fast Fourier Transformation,
and the mean FCL was determined by the peak power frequency in 20 epochs at each
recording. The LV ejection fraction was lower in the DCM group (50 18%) than the control
(63 8%, p ¼ 0:001). The mean FCL was shorter in the DCM group (132 14ms) than the
control (151 23ms, p ¼ 0:007) and there was a signiﬁcant correlation between the FCL and
LV dimensions (p ¼ 0:03). Conclusion: In patients with persistent AF and LV dysfunction,
FCL was shorter in comparison with the control, and seemed to be inﬂuenced by LV
dimensions.
(J Arrhythmia 2006; 22: 92–97)
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Introduction
Atrial ﬁbrillation (AF) is one of the most common
forms of supra-ventricular tachyarrhythmia and is
markedly more prevalent among heart failure (HF)
patients than in the general population.1) Although
the importance of triggering atrial arrhythmias, such
as atrial premature contractions from pulmonary
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veins, has been emphasized in AF cases,2,3) the
mechanism of reentry is still important in its
maintenance.4–7)
As determinants for the reentry, the myocardial
refractory period plays a key role, and electrical
remodeling, i.e., the shortening of the atrial refrac-
tory period due to AF, is considered to exaggerate
the AF itself.8–11) In contrast, several investigators
have reported a prolongation of, or no change in, the
atrial electrophysiological properties (e.g., action
potential duration) in heart failure cases,12,13) prob-
ably due to the down-regulation of several potassium
channels.13) Therefore, it is unclear whether the atrial
refractoriness would be prolonged or shortened in
cases with AF and LV dysfunction because LV
dysfunction and AF can exaggerate each other.
Intracardiac catheterization is the only direct
measurement for evaluation of atrial refractoriness,
but it is not appropriate for evaluating repeatedly or
frequently in the clinical setting. Because the atrial
ﬁbrillation wave (f-wave) in a surface ECG reﬂects
the complexity of activation wave fronts in the atria,
analysis of the f-wave may give a useful parameter
for the atrial electrophysiological properies.14–20) In
previous reports, ﬁbrillation cycle length (FCL)
calculated from spectral analysis of the f-waves in
the surface ECG showed a signiﬁcant correlation
with atrial refractoriness.19,20)
In the present study, we analyzed the f-waves in
cases with persistent AF and LV dysfunction to
clarify the inﬂuence of LV dysfunction on the atrial
electrophysiological properties in AF cases.
Methods
Subjects
The study population consisted of 43 consecutive
patients with persistent AF. Of the 43 patients, 14
had dilated cardiomyopathy (DCM group) as the
basic heart disease and the remaining 29 patients did
not have organic heart disease (control group).
Persistent AF was deﬁned as AF which can be
terminated, but is not self-terminating. The contin-
uation of the AF was conﬁrmed by recording
electrocardiograms three times during a 2–4 week
period. For patient selection, the subjects had to
satisfy the following criteria. (1) Clinical sympto-
matic level of New York Heart Association class
1–2. (2) No anti-arrhythmic administration (i.e.,
Vaughan Williams class I and III) for at least ﬁve
drug half-lives. Concomitant control of the ventric-
ular rate with a calcium channel antagonist, beta-
blocker or digitalis was permitted. (3) Patients with
renal dysfunction (serum creatinine levels >2:0mg/
dL) or severe liver dysfunction were excluded.
Patients with DCM were diagnosed by cardiac
catheterization including coronary angiography, left
ventriculography and left ventricular biopsy. They
were treated with medication in accordance with the
guidelines for therapy of DCM, including angioten-
sin-converting enzyme inhibitors, beta-blockers or
diuretics. The patients in the control group under-
went physical examination and echo-cardiography to
exclude any underlying structural disease.
Evaluation of the patients’ basic status
Echocardiography was performed with SONOS
5500 (Hewlett-Packard, Tokyo, Japan) to evaluate
the left atrial dimension, left ventricular (LV)
ejection fraction, LV end-diastolic dimension and
LV end-systolic dimension. Plasma B-type natriu-
retic peptide (BNP) concentration levels were meas-
ured in all patients except three in DCM and one
patient in the control group. Blood samples for BNP
were obtained at the time of ECG recording.
Recording of surface ECG and analysis of
ﬁbrillation waves
All patients underwent digitized 12-lead ECG
recording at a steady state and all data were stored
on-line on a microcomputer at a sampling rate of
1 kHz. The recording time of day was ﬁxed between
9:00 and 12:00 am to exclude the inﬂuence of
autonomic nervous system activation levels.
Out of the 12 lead ECG traces, the recording in V1
lead was used in this study because the f-wave is
usually most prominent in this lead. To obtain pure
f-wave traces, a QRS-T wave template was made
by a signal-averaged ECG, then the template was
subtracted from the original ECG traces in the digital
data.18) Frequency analysis was performed oﬀ-line
on a microcomputer (Bimutas II, KISSEI COMTEC
Co. Ltd., Matsumoto, Japan). Frequency analysis of
the subtracted ECG involved three steps including
1) bandpass ﬁltering, 2) application of a Hamming
window and 3) 4096-point fast Fourier transforma-
tion. A 50% overlap of adjacent spectral analyses
allowed the use of an average of 20 epochs of
analyses within a single 44-sec data set.18) After
spectral analysis, recordings were displayed as
power spectra. Power spectra were quantiﬁed by
measuring the peak frequency signal with the
maximum magnitude derived from each epoch.
The peak frequency of the spectrum in the 3–12Hz
range was converted to a cycle length (CL in ms ¼
1;000/frequency) and deﬁned the ﬁbrillation cycle
length (FCL) which was averaged from 20 epochs.
Temporal variability was expressed as the FCL
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coeﬃcient of variation (FCL-CV) of 20 consecutive
epochs.
All study protocols were performed with the
permission of the ethics committee of Kitasato
University and written informed consent was ob-
tained before study entry.
Statistical analysis
All data are expressed as mean SD. An un-
paired t-test was used to compare parametric
parameters between the two groups and categorical
parameters were compared using 2 analysis. The
correlations between FCL and echocardiographic
parameters were analyzed using all patient data and
Pearson’s simple correlation coeﬃcient was used.
Results were considered statistically signiﬁcant at
p < 0:05.
Results
Table 1 summarizes the clinical characteristics of
the patients in this study. There were signiﬁcant
diﬀerences between the two groups in echocardio-
graphic data because diﬀerences in the basic heart
disease. The number of beta-blocker or angiotensin-
converting enzyme inhibitor prescriptions was high-
er in the DCM group than the control reﬂecting
therapy for heart failure. There was no signiﬁcant
diﬀerence in other clinical background data except
for patient age.
Figure 1 shows FCL and FCL-CV data in the two
groups. The FCL was signiﬁcantly shorter in the
DCM group (132 14ms) than in the control group
(151 23ms, p ¼ 0:007), but there was no signiﬁ-
cant diﬀerence in the FCL-CV data between the two
groups (DCM 12 6% vs. control 13 7%, NS).
Figure 2 shows the relationships between FCL data
and the echocardiographic parameters. In each
analysis, primary regression was calculated using
all the data for the two groups. Although LAD did
not show a signiﬁcant correlation with FCL, left
ventricular dimensions (LVDd and LVDs) showed a
signiﬁcant negative correlation with FCL. LVEF
tended to show a very weak positive correlation with
FCL, but it was not signiﬁcant.
Because there were diﬀerences in age and med-
Table 1 Clinical characteristics of the patients.
DCM
(n ¼ 14)
Control
(n ¼ 29)
Age (years old) 58 16 70 8 p ¼ 0:004
Gender (F/M) 2/12 8/21 NS
AF duration (months) 63 52 61 56 NS
LV ejection fraction
(%) 50 18 63 8 p ¼ 0:001
LV end-diastolic
dimension (mm) 55 8 51 6 p ¼ 0:04
LV end-systolic
dimension (mm) 40 9 33 6 p ¼ 0:002
Left atrial
dimension (mm) 49 7 49 9 NS
BNP (pg/mL) 243 363 150 103 NS
Medications
Digitalis 11 (79%) 21 (72%) NS
Beta blocker 10 (71%) 8 (28%) p ¼ 0:02
ACE inhibitor 12 (86%) 6 (21%) p ¼ 0:0002
DCM = dilated cardiomyopathy; AF = atrial ﬁbrillation;
LV = left ventricular; BNP = B-type natriuretic peptide;
ACE = angiotensin-coverting enzyme
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Figure 1 Comparison of FCL and
FCL-CV data between the two
groups.
This ﬁgure shows the FCL (left panel)
and FCL-CV (right panel) data of
the two groups. In each panel, small
circles indicate the individual data and
large circles with SD bars show mean
data. FCL was signiﬁcantly shorter in
the DCM group (132 14ms) than in
the control group (151 23ms, p ¼
0:007), but there was no signiﬁcant
diﬀerence in FCL-CV data between the
two groups (DCM 12 6% vs. control
13 7%, NS). See text for discussion.
FCL = ﬁbrillation cycle length, FCL-
CV = FCL coeﬃcient of variation.
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ication between the two groups, the correlation
between these parameters and FCL was also eval-
uated. In total, FCL and age tended to show a weak
positive correlation (r ¼ 0:24) but it was not sig-
niﬁcant (p ¼ 0:16). There was no signiﬁcant diﬀer-
ence in the FCL between the two groups with and
without medications of angiotensin-converting en-
zyme inhibitors and/or anigiotensin receptor block-
ers (138 21ms vs. 150 22ms, NS), beta-block-
ers (144 27ms vs. 145 19ms, NS), or calcium
blockers (158 21ms vs. 141 21ms, NS).
Discussion
The present study evaluating the FCL in patients
with persistent AF and LV dysfunction revealed
some interesting ﬁndings. First, FCL was shorter in
the DCM group than the control, although FCL-CV
did not show a signiﬁcant diﬀerence. Second, there
were signiﬁcant negative correlations between FCL
and LV dimensions, although left atrial dimension or
LV ejection fraction did not show signiﬁcant
correlations.
Spectral analysis of atrial ﬁbrillation waves in
surface ECG
Previous studies with experimental models re-
ported that atrial refractoriness is shortened as a
result of atrial electrical remodeling in an AF
condition.8–11) Although electrical remodeling is
considered to occur even in clinical cases, little is
known about this phenomenon, mainly because of
the technical limitation in measuring the atrial
eﬀective refractory period (ERP). Measurement of
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Figure 2 Relationships between FCL data and echocardiographic parameters.
This ﬁgure shows the relationships between FCL data and the echocardiographic parameters, i.e., left atrial dimension (LAD: panel A), left
ventricular ejection fraction (LVEF: panel B), left ventricular end-diastolic dimension (LVDd: panel C) and left ventricular end-systolic
dimension (LVDs: panel D). Closed circles indicate individual data of DCM patients and open circles show those of the control patients. In
each analysis, primary regression was calculated among the whole data for the two groups and a regression line was drawn if it was
signiﬁcant. Although LAD did not show a signiﬁcant correlation with FCL, LVDd and LVDs showed a signiﬁcant negative correlation
with FCL. LVEF tended to show a very weak positive correlation with FCL, but it was not signiﬁcant. See text for discussion.
FCL = ﬁbrillation cycle length.
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ERP using premature stimulus via a catheter is the
standard method, but it is invasive and it is
impossible to evaluate the ERP during AF.
Recent studies have reported a new method for
noninvasive assessment of human AF cycle length
using surface ECG with spectral analysis,18–20) and a
signiﬁcant correlation between the frequency content
of the surface ECG and the intracardiac electro-
grams. Therefore, spectral analysis of f-waves in
surface ECG is a feasible method to evaluate the
atrial refractoriness in humans, and it was used in
this study to evaluate the electrical remodeling in
patients with persistent AF. In the present study, we
chose the V1 lead recording for the analysis as did
the previous studies, and as it was technically
diﬃcult to choose the lateral chest leads because of
the low amplitude of the f-wave in these leads.
Because of the distance from the cardiac surface, this
recording seems to reﬂect the electrophysiologic
properties of the right atrium and not the left atrium.
Our results might be misleading if the right and left
atrial conditions were diﬀerent, but the patients in
this study were considered to have similar conditions
in the two atria upon diagnosis of DCM and long
lasting AF.
LV dysfunction and atrial electrophysiological
properties
Although several experimental reports document-
ed the shortening of atrial ERP under continuous
rapid atrial activation, i.e., AF,8–11) other studies
reported no change in ERP in heart failure. Li et al.
studied the eﬀect of rapid atrial pacing on atrial ERP
in heart failure, and reported that the atrial ERP and
wavelength were not aﬀected by rapid pacing,
whereas they were signiﬁcantly shortened by rapid
pacing in patients without heart failure.12) The
precise mechanism is unclear, but the down-regu-
lation of the potassium channel, especially the
transient outward current channel (Ito), which is
triggered by an increased atrial wall stress, is
considered to play an important role.13)
Therefore, the result of the electrical remodeling
trigged by AF and LV dysfunction is questionable,
especially in clinical cases. Sanders et al. evaluated
the atrial electrophysiological characteristics in
patients with heart failure and reported that patients
with heart failure demonstrated an increase in atrial
ERP with no change in the heterogeneity of
refractoriness.21)
These results suggest that the LV dysfunction
suppresses the shortening of atrial ERP in the
process of atrial electrical remodeling in AF, and
diﬀer from the results of the present study. Our
results indicate shortening of atrial ERP in patients
with LV dysfunction, and that the shortening was
even exaggerated by the presence of LV dysfunction.
Because an increase in the LV dimension would lead
to larger mitral regurgitation or higher end-diastolic
pressure, it is reasonable to correlate it with more
severe heart failure and a higher chance of AF in
clinical cases. Therefore, if AF causes the shortening
of atrial ERP, our result is quite reasonable.
The reason for the diﬀerence between the results
of previous reports and the present study is unclear,
but one possible explanation is the diﬀerence in the
method for the ERP measurement. Because our
study used the spectral analysis of the f-wave in the
surface ECG, the recording might reﬂect plural
simultaneous atrial activations; the shorter FCL in
our study may reﬂect not only shorter ERP, but also
more complicated atrial activations. It is also
reasonable to assume a higher number of simulta-
neous wave fronts on the surface of an enlarged
chamber. Because we studied DCM patients with LV
dysfunction in this study, it is unclear whether this
result was speciﬁc or nonspeciﬁc for patients with
DCM. This point should be addressed by analyzing
the data in patients with LV dysfunction due to
causes other than cardiomyopathy.
Study limitations
There were a few limitations in this study. First,
although the study reached a few conclusions, they
were evaluated in a relatively small number of
patients. Second, the AF duration data were mainly
obtained from their history and ECG recordings over
a limited time, so asymptomatic AF or unknown
conversion cannot be excluded. Third, there were
some diﬀerences in the clinical characteristics of the
patients in the two groups (i.e., age or medications).
Although there was no signiﬁcant correlation be-
tween FCL and those parameters in total, it is
unclear whether these factors could aﬀect atrial
electrical remodeling in clinical cases. Further
studies are needed to answer to these questions.
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